AstraZeneca PLC
AZNNYSEMarket cap
$281.60B
Employees
96,100
Exchange
NYSE
Founded
1999
About AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Country
US
Website
www.astrazeneca.comAZN news
Recent studies demonstrate significant progress in bladder cancer treatment options and outcomes for patients. Simultaneously, researchers have identified emerging environmental factors that may increase bladder cancer risk, prompting further investigation. These findings could reshape clinical approaches and public health strategies in oncology.
GlobeNewswire Inc. · May 15, 2026